Skip to main content
Terug
CHIZF logo

China Traditional Chinese Medicine Holdings Co. Limited

Datakwaliteit: 100%
Overbought
CHIZF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 0,27
€ 0,00 (0,00%)
Marktkapitalisatie: 1,38B
Dagbereik
€ 0,27 € 0,27
52-Weeksbereik
€ 0,24 € 0,35
Volume
100
50D / 200D Gem.
€ 0,27 / € 0,27
Vorige Slotkoers
€ 0,27

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -4,1 0,4
P/B 0,1 2,9
ROE % -1,6 3,7
Net Margin % -2,3 3,8
Rev Growth 5Y % -6,8 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue declined -6,82% annually over 5 years
Earnings declined -716,35% over the past year
Debt/Equity of 0,12 — conservative balance sheet
Generating 2,07B in free cash flow
PEG of 0,04 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,17%

Groei

Revenue Growth (5Y)
-6,82%
Revenue (1Y)-12,99%
Earnings (1Y)-716,35%
FCF Growth (3Y)91,45%

Kwaliteit

Return on Equity
-1,60%
ROIC0,97%
Net Margin-2,32%
Op. Margin2,07%

Veiligheid

Debt / Equity
0,12
Current Ratio2,29
Interest Coverage3,08

Waardering

P/E Ratio
-4,13
P/B Ratio0,07
EV/EBITDA-0,59
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -12,99% Revenue Growth (3Y) -10,97%
Earnings Growth (1Y) -716,35% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -6,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14,36B Net Income (TTM) -333,24M
ROE -1,60% ROA -1,03%
Gross Margin 48,09% Operating Margin 2,07%
Net Margin -2,32% Free Cash Flow (TTM) 2,07B
ROIC 0,97% FCF Growth (3Y) 91,45%
Safety
Debt / Equity 0,12 Current Ratio 2,29
Interest Coverage 3,08 Dividend Yield 0,04%
Valuation
P/E Ratio -4,13 P/B Ratio 0,07
P/S Ratio 0,10 PEG Ratio 0,04
EV/EBITDA -0,59 Dividend Yield 0,04%
Market Cap 1,38B Enterprise Value -175,02M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,36B 16,51B 18,12B 14,30B 19,05B
Net Income -333,24M 54,07M 1,29B 764,49M 1,93B
EPS (Diluted) -0,07 0,01 0,26 0,15 0,38
Gross Profit 6,91B 7,86B 9,27B 7,20B 11,83B
Operating Income 297,75M 335,59M 1,43B 1,06B 2,75B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 32,36B 35,06B 37,07B 35,62B 36,39B
Total Liabilities 8,94B 11,13B 13,13B 12,67B 13,73B
Shareholders' Equity 20,48B 21,20B 21,16B 20,17B 19,72B
Total Debt 2,49B 4,02B 5,16B 5,04B 5,06B
Cash & Equivalents 4,05B 3,87B 3,02B 3,07B 2,89B
Current Assets 17,72B 18,84B 19,80B 17,97B 18,20B
Current Liabilities 7,74B 7,80B 9,33B 10,10B 8,76B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#565 of 820
35

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026